NASDAQ:IMRN Immuron Q1 2026 Earnings Report $1.11 +0.02 (+2.02%) As of 12:59 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Immuron EPS ResultsActual EPS-$0.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuron Revenue ResultsActual Revenue$1.40 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuron Announcement DetailsQuarterQ1 2026Date4/30/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Immuron Earnings HeadlinesImmuron Ltd ADR (IMRN)September 26, 2026 | investing.comImmuron Releases Comprehensive 2026 Annual ReportSeptember 24, 2026 | tipranks.comHOST Just Entered the AI Data Center Race in a BIG WayHost Digital Inc (NYSE American: HOST) has completed its merger with Healthy Choice Wellness Corp as of September 17, 2026, entering public markets as a developer of U.S. data centers built for AI and high-performance computing. The company already holds a 15-year take-or-pay lease covering roughly 43 MW of critical IT load at its northeast Oklahoma campus, representing approximately 1.25 billion dollars in contracted base-term rent with 3 percent annual escalators, set to begin in Q1 2027.October 8 at 1:00 AM | Trading Wire (Ad)Immuron Files 2026 Corporate Governance Statement with ASXSeptember 24, 2026 | tipranks.comImmuron Showcases Oral Antibody Platform at Coffee Microcaps ConferenceSeptember 21, 2026 | tipranks.comImmuron Ltd ADR IMRNSeptember 9, 2026 | morningstar.comMSee More Immuron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immuron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuron and other key companies, straight to your email. Email Address About ImmuronImmuron (NASDAQ:IMRN) Limited (NASDAQ:IMRN) is an Australian biopharmaceutical company focused on developing and commercializing orally delivered immunotherapies. Its products are based primarily on antibodies derived from hyperimmune bovine colostrum and are designed to act locally in the gastrointestinal tract rather than enter the bloodstream. The company’s leading product is Travelan, an oral treatment intended to help prevent travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC). Travelan has been marketed in several countries, including the United States, Canada, and Australia, subject to the regulatory status and labeling requirements in each jurisdiction. Immuron also conducts research on additional oral antibody-based therapies for gastrointestinal and infectious diseases. Its development programs have included candidates such as IMM-124E and IMM-529, which have been investigated for potential applications involving gastrointestinal disorders and infections. The company is headquartered in Melbourne, Australia, and serves international markets through regulatory, commercial, and distribution activities.View Immuron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand ExplodesDoes Lemonade’s Growth Signal Profits Ahead?Wall Street Is Betting These 3 Beaten-Down Stocks Have More Room to Run Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
